[HTML][HTML] Adopting drug repurposing to overcome drug resistance in cancer
E Shankar, V Subramaniam… - Frontiers in Cell and …, 2023 - frontiersin.org
Despite significant technological advances the etiology of cancer and mechanism disease
progression, and their translation into therapeutic benefits has been considerably slow …
progression, and their translation into therapeutic benefits has been considerably slow …
[HTML][HTML] Repurposed Drugs Targeting Cancer Signaling Pathways: Dissecting New Mechanism of Action Through In Vitro and In Vivo Analyses
E López-Urrutia, T Padilla-Benavides… - Frontiers in …, 2021 - frontiersin.org
In today's fast-paced society, efficiency is critical in many aspects, especially in costly,
resourceintensive processes such as drug discovery and development. Technological …
resourceintensive processes such as drug discovery and development. Technological …
[HTML][HTML] Revitalizing Cancer Treatment: Exploring the Role of Drug Repurposing
RR Malla, S Viswanathan, S Makena, S Kapoor… - Cancers, 2024 - mdpi.com
Simple Summary Drug repurposing is emerging as a promising avenue for addressing
clinical challenges in treating drug-resistant and metastatic cancers. As a case study, some …
clinical challenges in treating drug-resistant and metastatic cancers. As a case study, some …
Turning liabilities into opportunities: Off-target based drug repurposing in cancer
Targeted drugs and precision medicine have transformed the landscape of cancer therapy
and significantly improved patient outcomes in many cases. However, as therapies are …
and significantly improved patient outcomes in many cases. However, as therapies are …
[PDF][PDF] Drug repositioning: extracting added value from prior R&D investments
HAM Mucke - Insight Pharma Reports, 2010 - researchgate.net
Drug repurposing (an approach to drug development that is also known as drug
repositioning, reprofiling, or retasking) has become a matter of intense interest during the …
repositioning, reprofiling, or retasking) has become a matter of intense interest during the …
Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds
Highlights•De novo anticancer drug discovery is challenging and repurposing in oncology is
a promising field.•Drug repositioning increasingly emerges as faster, cheaper and …
a promising field.•Drug repositioning increasingly emerges as faster, cheaper and …
[HTML][HTML] repurposed drugs targeting cancer signaling pathways: clinical insights to improve oncologic therapies
C Pérez-Plasencia, T Padilla-Benavides… - Frontiers in …, 2021 - frontiersin.org
The analyses of drug development from different standpoints show how resource-intensive
this process is, with two main disadvantages: time and cost. It takes 11 to 14 years to …
this process is, with two main disadvantages: time and cost. It takes 11 to 14 years to …
Drug repurposing for cancer therapy in the era of precision medicine
K KW To, W Cho - Current Molecular Pharmacology, 2022 - ingentaconnect.com
Drug repurposing refers to the identification of clinically approved drugs with the known
safety profiles and defined pharmacokinetic properties for new indications. Despite the …
safety profiles and defined pharmacokinetic properties for new indications. Despite the …
[HTML][HTML] Drug Repurposing: Exploring Potential Anti-Cancer Strategies by Targeting Cancer Signalling Pathways
N Haddad, SM Gamaethige, N Wehida, A Elbediwy - Biology, 2024 - mdpi.com
Simple Summary The repurposing of drugs is an important and rapidly growing field in the
treatment of cancer. The main advantage of drug repurposing is using currently established …
treatment of cancer. The main advantage of drug repurposing is using currently established …
[HTML][HTML] “Hard” drug repurposing for precision oncology: the missing link?
P Pantziarka, G Bouche, N André - Frontiers in Pharmacology, 2018 - frontiersin.org
Drug repurposing is at the heart of precision oncology. The move from tissue-or cancer-
specific treatments to genomic-or actionable-target treatments necessarily entails the reuse …
specific treatments to genomic-or actionable-target treatments necessarily entails the reuse …